RxDoctor Payments Data

Vandana Mathur

Nephrology · Woodside, CANPI 1699078915

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $769,375 of the $769,375 with a category attached, or 100.0%. Myovant Sciences Inc. accounts for 92.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2021 at $407,813 and has fallen 99.1% since, to $3,500 in 2025. Among nephrology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$769,375in general payments, 2019–2025

Across 49 payments — averaging $15,702 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Myovant Sciences Inc.$714K
  • Biogen$53K
  • Sumitomo Pharma America, Inc.$2K

What the payments were for

  • Consulting fees$769,375100%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Myovant Sciences Inc.37$714,488
Biogen7$52,750
Sumitomo Pharma America, Inc.5$2,138

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$769,375 in reported general payments places this provider in the 95th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California →

Other nephrology in Woodside

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →